HumanperipheralbloodCD14+monocytesdifferentiatingtomacrophages

Monocytesarefoundinthecirculatingperipheralbloodwheretheymakeup10-20%ofthetotalmononuclearcellpopulation.MonocytesarecharacterizedbytheirphenotypicexpressionofCD14,andthus,arecommonlycalledCD14+monocytes.Theyplayanimportantroleinhostdefenseascirculatingmonocytesanddifferentiationintotissuemacrophages,andcandifferentiateintodendriticcellswithpotentantigen-presentingcapABIlity.

CellsYouCanCountontoPerform

LonzaHumanPeripheralBloodCD14+Monocytesareisolatedfromperipheralbloodofscreened,healthy,untreated(non-mobilizedperipheralblood)donors.Briefly,mononuclearcells(MNCs)areisolatedfromapheresisderivedperipheralblood.TheMNCpopulationisthenfurtherpurifiedviapositiveimmunomagneticselectiondirectedagainstCD14.

CryopreservedCD14+MonocytesareguaranteedtoexpressCD14andwillcontaineither≥10,20,or40millionviablecellsperampouledependingupontheproductordered.HIV-1,hepatitisBandhepatitisCarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.

ChoicesinCellTypeandTissueSource

Hematopoieticandimmuneresearchrequiresavarietyofdonorsandcelltypes.That"swhyLonzaoffersmanydifferentperipheralbloodcelltypesfromavarietyofdonors,includingPBMCsanddendriticcells,amongothers.Inaddition,ifyouareinterestedinexploringthedifferencesbetweenmonocytesindifferentmaturationstatesorfromdifferenttissues,weofferbonemarrowmononuclearcellsandcordbloodmononuclearcells.

SupportedbyLonzaMedia
Therecommendedmediumvariesbyapplication.PleasecontactScientificSupportforadditionalculturingrecommendations.

• ToMaintaintheMonocytePhenotype:
  RPMI+10%FetalBovineSerum +2mM L-glutamine+10ng/mlrHUM-CSF(optional)


• ToProduceMacrophages:
  RPMI+10%FetalBovineSerum+2mML-glutamine+1%SodiumPyruvate+1%Non-EssentialAminoAcids+25ng/mlrHUM-CSF


• ToProduceDendriticCells:
  LGM-3™LymphocyteGrowthMedium+50ng/mlGM-CSF+50ng/mlIL-4

Mediarecommendationsformacrophageanddendriticcelldifferentiationarerecommendationsonly.LonzaCD14+monocytesarenotroutinelyqualitycontroltestedformacrophageordendriticcelldifferentiationanddifferentiationisnotguaranteedunderthecellwarranty.Additionalfactorsincludingextracellularmatrixesorculturingconditionsmayberequiredtoproducedifferentiation.

LonzaguaranteestheperformanceofClonetics™/Poietics™cellsonlyifappropriateClonetics™/Poietics™mediaandreagentsareusedexclusivelyandtherecommendedstorageanduseprotocolsarefollowed.Anymodificationsmadetotherecommendedcellsystemsincludingtheuseofalternativemedia,reagentsorprotocols,willvoidcellandmediaperformanceguarantees.Ifyouneedassistanceinselectingtheappropriatemedia,reagents,orprotocol,pleasecontactLonzaScientificSupport.

龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。